Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00773955 · ClinicalTrials.gov registry record · Phase 2

R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

A Phase 2 study of Extensive-stage Small-cell Lung Cancer and Recurrent Small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
15
Enrollment target
1
Study location

NCT00773955: Completed Phase 2 study of Extensive-stage Small-cell Lung Cancer and Recurrent Small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).

NCT00773955 is a Phase 2 study of Extensive-stage Small-cell Lung Cancer and Recurrent Small Cell Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 15 participants, below the 175-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00773955, a Phase 2 study of Extensive-stage Small-cell Lung Cancer and Recurrent Small Cell Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This phase II trial is studying how well R-(-)-gossypol acetic acid works in treating patients with recurrent extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as R-(-)-gossypol acetic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Primary Outcome

The number of successes will be estimated by counting the number of participants with confirmed responses. A confirmed tumor response is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: A Complete Response (CR) requires the disappearance of all target lesions A Partial Response (PR) requires a \>=30% decrease in the sum of the longest di

Conditions Studied

Extensive-stage Small-cell Lung Cancer Recurrent Small Cell Lung Cancer

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER pharmacological study
  • DRUG R-(-)-gossypol acetic acid

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2008-11
Est. Completion 2010-08
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00773955 record still lists

NCT00773955 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 175-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.

NCT00773955 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT00773955 about?

NCT00773955 is a clinical study titled "R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer". This phase II trial is studying how well R-(-)-gossypol acetic acid works in treating patients with recurrent extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as R-(-)-gossypol acetic acid, work in different ways to stop the growth of tumor cells, either by killing the cells ...

What is the current status of trial NCT00773955?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2008-11. Estimated completion is 2010-08.

What conditions does trial NCT00773955 study?

This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer, Recurrent Small Cell Lung Cancer.

What interventions are being tested in trial NCT00773955?

The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), R-(-)-gossypol acetic acid (DRUG).

Who is sponsoring clinical trial NCT00773955?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00773955 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive-stage Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00773955's enrollment target sits among peer trials

15 24th of 25 higher than 2 of 25 other Extensive-stage Small-cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Extensive-stage Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00773955, the US trial registry maintained by the National Library of Medicine. NCT00773955 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.